Biochemical profile in patients with anxious depression under the treatment with serotonergic antidepressants with different mechanisms of action

Human Psychopharmacology

Volumn 21, Issue 2, 2006, Pages 109-115

  Uzbekov, Marat G ^a   Misionzhnik, Eduard Y ^a   Maximova, Natella M ^a   Vertogradova, Olga P ^a  

^a Moscow Research Institute of Psychiatry   (Russian Federation)

Author keywords

Anxious depression; Biochemical profiles; Setraline; Tianeptine

Indexed keywords

ALBUMIN; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AMINE OXIDASE (COPPER-CONTAINING); ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SERUM ALBUMIN; THIAZEPINES;

EID: 33644626526     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.749     Document Type: Article

References (37)

1. Ansseau M. 1993. The paradox of tianeptine. Eur Psychiatry 8(Suppl. 2): 89-93.
2. Babb AL, Farrell PC, Uvelli DA, Scribner BH. 1972. Hernodialyzer evaluation by examination of solute molecular weight spectra. Trans Amer Soc Artif Int Organs 18: 98-105.
3. Balakleevski AI. 1976. Colorimetric method of estimation of serum monoamine oxidase activity. Lab Delo 3: 151-153 (in Russian).
4. Bech P. 1992. Acute therapy of depression. J Clin Psychiat 54(Suppl. 8): 19-28.
5. Beckman KB, Ames BN. 1998. The free radical theory of aging matures. Physiol Rev 78: 547-581.
6. Chalenko VV. 1991. Possible causes of the increase of concentration of molecules of middle mass in pathologic states. Pathol Physiol and exp Therap 4: 13-14.
7. Clayton PJ. 1990. The co-morbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 51(Suppl. 11): 35-39.
8. Cloninger CR. 1990. Co-morbidity of anxiety and depression. J Clin Psychopharmacol 10: 43S-46S.
9. Doogan DP, Caillard V. 1992. Sertraline in the prevention of depression. Br J Psychiatry 160: 217-222.
10. Gorkin VZ. 1985. Studies on the nature and specific inhibition of monoamine oxidases. In Neurophannacology '85, Keleman K, Magyar K, Visi ES (eds). Akademiai Kiado: Budapest; 9-14.
11. Gryzunov YA, Miller YI, Dobretsov GE, Pestova AB. 1994. Fluorescent assay for the determination of human serum albumin mass concentration. Clin Lab Diagnostica 5: 27-31 (in Russian).
12. Gryzunov YA, Syreytschikova TI, Komarova MN, et al. 2000. Serum albumin binding sites properties in donors and schizophrenia patients: the study of fluorescence decay of the probe K-35 using S-60 synchrotron pulse excitation. Nuclear Instruments and Methods in Physics Research 448(Section A): 478-482.
13. Hamilton M, 1988. Distinguishing between anxiety and depressive disorders. In Handbook of Anxiety Disorders, Last CA, Hersen M (eds). Pergamon Press: Oxford; 143-155.
14. Kasper S. 2001. Depression and anxiety - separate or continuum. World J Biol Psychiatry 2: 162-163.
15. Kato G, Weitsch AF 1988. Neurochemical profile of tianeptine, a new antidepressant drug. Clin Neuropharmacol 11(Suppl. 2): S43-S50.
16. Kragh-Hansen U, Chuang, Otagiri M. 2002. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25: 695-704.
17. Kovalevskii AN, Nifantieva OE. 1989. About the screening method of the estimating of middle mass molecules. Lab delo 10: 13-18.
18. Lamperi S, Carozzi S, Trasforini D, et al. 1979. Preliminary results of the effects of dialytic treatment in chronic schizophrenia. Minerva Nefrol 26: 109-113.
19. Loo H, Saiz-Ruiz J, Costa e Silva JA, et al. 2001. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. Hum Psychopharmacol Clin Exp 16: S31-S38.
20. Malakhova MYa, Zubatkina. OV. 2004. Metabolic Criterion of Homeostasis. Pomorskii Universitet: Arkhangel'sk (in Russian).
21. Maximova NM, Vertogradova OP, Uzbekov MG. 2004. Dynamics of anxious depression under tianeptine and sertraline treatment: comparative clinical-biochemical investigation. World Psychiatry 3(Suppl. 1): 277.
22. McEwen CM, Cohen JD. 1963. An amine oxidase in normal human serum. J Lab Clin Medicine 62: 766-776.
23. Moin VM, Misionzhnik EY, Kuznetsova ZI, et al. 1994. Some characteristics of the method and reagents for the fluorescent determination of effective and total serum albumin concentration. Clin Lab Diagnostica 5: 33-35 (in Russian).
24. Nikolaichik W, Moin VM, Kirkovski VV, et al. 1991. The method of estimation of middle molecules. Lab Delo 10: 13-18 (in Russian).
25. Nuller YL, Mikhalenko IA. 1988. Affective Psychoses. Nauka: Leningrad (in Russian).
26. Prilipko LL, Erin AN, Beliaev BS, Piatnitskii AN, Siuniakov SA. 1987. Activation of lipid peroxidation in the bodies of schizophrenic and manic-depressive patients. Zh Nevropatol Psikhiatr 87: 100-103 (in Russian).
27. Ringoir S, Vanholder R, Massry SG (eds). 1987. Uremic Toxins. Plenum Press: New York-London.
28. Rodney J, Prior N, Cooper B. et al. 1997. The comorbidity of anxiety and depression. Austral and New Zealand J Psychiatry 31: 700-703.
29. Stahl SM. 1985. Peripheral models for the study of neurotransmitter receptors in man. Psychopharmacol Bul 21: 663-671.
30. Tollefson GD, Souetre E, Thomander L, Potvin JH. 1993. Comorbid anxious signs and symptoms in major depression impact on functional work capacity and comparative treat outcomes. Int Clin Psychopharmacol 8: 281-293.
31. Turianitsa IM, Mishanich H, Rostoka LM. 1988. Middle molecule spectrum of the blood serum in patients with a continuously progressive paranoid form of schizophrenia undergoing treatment. Zh Nevropatol Psikhiatr 88: 109-111 (in Russian).
32. Umanskii MA, Pinchuk LB, Pinchuk VG. 199 1. Syndrome of Endogenous Intoxication. Naukova Dumka: Kiev.
33. Uzbekov MG, Misionzhnik EY. 2000. Nonspecific syndrome of endogenous intoxication as an integral component of pathogenesis of psychic disorders. Russian Journal of Psychiatry 4: 56-65 (in Russian).
34. Uzbekov MG, Misionzhnik EY, Neduva AA, Malin DI. 1995. Dynamics of the level of middle molecules and activity of some enzymes of neurotransmitter metabolism in patients with resistant endogenous psychosis under plasmapheresis. Behavioural Pharmacol 6(Suppl. 1): 61.
35. Voloshina ON, Moskvitina TA. 1985. Method of estimation of platelet monoamine oxidase activity. Lab Delo 5: 289-291 (in Russian).
36. World Health Organization. 1992. The Tenth Revision of the International Classification of Diseases and Related Health Problems. WHO: Geneva.
37. World Health Organization. 1999. Composite International Diagnostic Interview (CIDI), Version I.O.: Geneva, WHO.